A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer

INTRODUCTION: This is a retrospective analysis to assess the safety and efficacy of abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC) patients treated at tertiary care institute. MATERIALS AND METHODS: The clinical records of mCRPC patients treated with AA at our tert...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Amit, Shrirangwar, Sameer, Noronha, Vanita, Sable, Nilesh, Agarwal, Archi, Popat, Palak, Bhattacharjee, Atanu, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
ORIGINAL ARTICLE: Genitourinary Cancers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956584/
https://www.ncbi.nlm.nih.gov/pubmed/31956615
http://dx.doi.org/10.4103/sajc.sajc_433_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956584/
https://www.ncbi.nlm.nih.gov/pubmed/31956615
http://dx.doi.org/10.4103/sajc.sajc_433_18

Ejemplares similares